Homologous Peptide Foldamer Promotes FUS Aggregation and Triggers Cancer Cell Death Visa övriga samt affilieringar
2024 (Engelska) Ingår i: Journal of the American Chemical Society, ISSN 0002-7863, E-ISSN 1520-5126, Vol. 146, nr 42, s. 28669-28676Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Fused in sarcoma (FUS), a multifunctional deoxyribonucleic acid (DNA)/ribonucleic acid (RNA)-binding protein, has been implicated in various cancer types, including sarcoma and leukemia. Despite its association with these diseases, there has been limited exploration of FUS as a cancer therapy target, primarily because its dynamic nature makes it difficult to target specifically. In this study, we explored a kind of beta-sheet peptide foldamer, named beta(4)-TAT, to influence FUS aggregation by targeting its RNA recognition motifs (RRM). This approach leverages the noncovalent interaction characteristics of peptide self-assembly processes. The beta(4) sequence, derived from the FUS RRM beta-sheet, in combination with TAT, a peptide known for its nuclear targeting capability, enables beta(4)-TAT to bind specifically to the analogous beta(4) sequence within FUS. Notably, beta(4)-TAT effectively induces FUS aggregation within cells, leading to the death of cancer cells. Our work developed a novel peptide foldamer-based strategy for inducing protein aggregation, paving the way for innovative therapeutic approaches in targeting FUS-associated cancers.
Ort, förlag, år, upplaga, sidor American Chemical Society (ACS), 2024. Vol. 146, nr 42, s. 28669-28676
Nationell ämneskategori
Neurovetenskaper Cell- och molekylärbiologi
Identifikatorer URN: urn:nbn:se:uu:diva-548972 DOI: 10.1021/jacs.4c03420 ISI: 001333398600001 PubMedID: 39403745 OAI: oai:DiVA.org:uu-548972 DiVA, id: diva2:1936364
2025-02-102025-02-102025-02-10 Bibliografiskt granskad